FDA Approves Expansion of CellCept (mycophenolate mofetil) Indication to Pediatric Heart Transplant and Pediatric Liver Transplant Populations
June 8, 2022 -- FDA has expanded the use of CellCept (mycophenolate mofetil) to prophylaxis of organ rejection in pediatric recipients of allogenic heart and allogeneic liver transplants aged 3 months and older in combination with other...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news
More News: Cardiology | Drugs & Pharmacology | Heart | Heart Transplant | Liver | Liver Transplant | Pediatrics | Transplant Surgery | Transplants | Urology & Nephrology